It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ETON’s FA Score shows that 2 FA rating(s) are green whilePCRX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ETON’s TA Score shows that 6 TA indicator(s) are bullish while PCRX’s TA Score has 5 bullish TA indicator(s).
ETON (@Pharmaceuticals: Generic) experienced а -0.58% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was -1.59% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.
ETON is expected to report earnings on Nov 12, 2025.
PCRX is expected to report earnings on Oct 30, 2025.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
ETON | PCRX | ETON / PCRX | |
Capitalization | 457M | 1.11B | 41% |
EBITDA | -342K | 28M | -1% |
Gain YTD | 27.928 | 31.529 | 89% |
P/E Ratio | 124.00 | 13.04 | 951% |
Revenue | 48.3M | 703M | 7% |
Total Cash | 17.4M | 494M | 4% |
Total Debt | 30.1M | 636M | 5% |
ETON | PCRX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 32 | 100 | |
SMR RATING 1..100 | 96 | 94 | |
PRICE GROWTH RATING 1..100 | 37 | 43 | |
P/E GROWTH RATING 1..100 | 6 | 100 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCRX's Valuation (58) in the Pharmaceuticals Other industry is in the same range as ETON (88) in the Pharmaceuticals Major industry. This means that PCRX’s stock grew similarly to ETON’s over the last 12 months.
ETON's Profit vs Risk Rating (32) in the Pharmaceuticals Major industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that ETON’s stock grew significantly faster than PCRX’s over the last 12 months.
PCRX's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as ETON (96) in the Pharmaceuticals Major industry. This means that PCRX’s stock grew similarly to ETON’s over the last 12 months.
ETON's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as PCRX (43) in the Pharmaceuticals Other industry. This means that ETON’s stock grew similarly to PCRX’s over the last 12 months.
ETON's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that ETON’s stock grew significantly faster than PCRX’s over the last 12 months.
ETON | PCRX | |
---|---|---|
RSI ODDS (%) | 3 days ago86% | 3 days ago81% |
Stochastic ODDS (%) | 3 days ago82% | 3 days ago76% |
Momentum ODDS (%) | 3 days ago81% | 3 days ago69% |
MACD ODDS (%) | 3 days ago79% | 3 days ago60% |
TrendWeek ODDS (%) | 3 days ago80% | 3 days ago79% |
TrendMonth ODDS (%) | 3 days ago79% | 3 days ago69% |
Advances ODDS (%) | 12 days ago82% | 7 days ago68% |
Declines ODDS (%) | 4 days ago81% | 3 days ago78% |
BollingerBands ODDS (%) | 3 days ago75% | 3 days ago72% |
Aroon ODDS (%) | 3 days ago84% | 3 days ago83% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SCVEX | 21.91 | 0.16 | +0.74% |
Hartford Schroders International Stk A | |||
HDIVX | 18.45 | 0.11 | +0.60% |
Janus Henderson International Div I | |||
MXMGX | 38.32 | 0.05 | +0.13% |
Empower T. Rowe Price Mid Cp Gr Inv | |||
FIJFX | 91.19 | -0.06 | -0.07% |
Fidelity Advisor Materials Z | |||
WTMVX | 12.29 | -0.02 | -0.16% |
Segall Bryant & Hamill Glb All Cp Retail |
A.I.dvisor tells us that ETON and ELAN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ETON and ELAN's prices will move in lockstep.
Ticker / NAME | Correlation To ETON | 1D Price Change % | ||
---|---|---|---|---|
ETON | 100% | +2.04% | ||
ELAN - ETON | 28% Poorly correlated | -0.22% | ||
PCRX - ETON | 27% Poorly correlated | -0.84% | ||
AQST - ETON | 27% Poorly correlated | N/A | ||
HROW - ETON | 25% Poorly correlated | -2.97% | ||
TKNO - ETON | 25% Poorly correlated | -2.29% | ||
More |
A.I.dvisor indicates that over the last year, PCRX has been loosely correlated with ALKS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PCRX jumps, then ALKS could also see price increases.
Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
---|---|---|---|---|
PCRX | 100% | -0.84% | ||
ALKS - PCRX | 34% Loosely correlated | +2.80% | ||
ELAN - PCRX | 31% Poorly correlated | -0.22% | ||
TEVA - PCRX | 29% Poorly correlated | +1.82% | ||
ETON - PCRX | 27% Poorly correlated | +2.04% | ||
NBIX - PCRX | 25% Poorly correlated | +1.21% | ||
More |